Freedom to Innovate and Freedom to Operate

Date:  Sat, 2006-04-01

M·CAM sponsors Soweto Gospel Choir concert in Charlottesville

Date:  Thu, 2006-03-30

M·CAM CEO Addresses WIPO Forum on the draft Substantive Patent Law Treaty in Geneva

Date:  Thu, 2006-03-02

Dr. David E. Martin March 2, 2006

Dr. David Martin, CEO of M·CAM and Intellectual Property Finance Fellow at the Batten Institute at University of Virginia’s Darden Graduate School of Business Administration will be addressing the World Intellectual Property Organization’s (WIPO) Open Forum on the draft Substantive Patent Law Treaty (SPLT) on March 2. The Forum was assembled by the member States of WIPO at the 32nd session of the General Assembly in the context of discussions on the establishment of a work plan for the Standing Committee on the Law of Patents (SCP) in respect of the draft SPLT. The SCP has been discussing the draft SPLT since May 2001. Although a number of issues in the draft SPLT have been agreed in principle, there are a number of outstanding issues that require further consideration. The Forum will address various issues that have been raised in the draft of the SPLT or that Member States may wish to include in the draft SPLT.

During this time of extreme international trade focus on matters of Intellectual Property law and enforcement, this Forum will bring together policy makers and experts from around the world to seek to better define the ground rules for improved patent treaties.

M·CAM, Inc. (M·CAM) is a full-service intellectual property rights actuarial company dedicated to developing, enabling and promoting uniform accountability and quality standards for the granting, use, and disposal of such rights in the global economy. From our pioneering work in creating the world’s first standards-based innovation collateralization financial products for banking and securities to our work on international grass-roots innovator enablement, M·CAM endeavors to balance the interests of the public and industrial development supporting creativity to build thriving economies.

Dr. Martin’s work with the Batten Institute at the Darden Graduate School of Business Administration at the University of Virginia and his related work at the Indian Institute for Management in Ahmedabad India has brought unprecedented curricular focus to areas of intangible asset risk management, finance, and accounting standards. In addition to his academic work, Dr. Martin has closely advised intellectual property based finance and investment programs in India, China, Denmark, the European Union, the United Kingdom, South Africa, the Islamic Republic of Iran, the United States, and the United Arab Emirates.

More information about the conference can be found at WIPO.

Dr. Martin’s conference materials can be found at: Materials.

M·CAM announces release of M·CAM DOORS™ Version 6 with Added Corporate Financial Data

Date:  Wed, 2006-02-01

Dr. David E. Martin February 1, 2006 M·CAM&#174, the world leader in intellectual property analytics and financial risk management, releases M·CAM DOORS&#153 Version 6, the gold standard intellectual property risk management system. In addition to the world’s largest standardized database of patents and patent related information, M·CAM DOORS&#153 Version 6 now provides access to SEC filings, more extensive legal status and patent family information, multi-lingual support in the Compass document viewer, and enhanced presentation and visualization features. In addition, Sextant, a world class competitive analysis and trending tool, has returned in a much more powerful form in M·CAM DOORS&#153 Version 6. For more information about the use of M·CAM DOORS&#153, please contact M·CAM at +1.434.979.7240 or visit us at www.m-cam.com.

M·CAM Presents IP-Backed Securities Trading Model to the Dubai International Financial Exchange (DIFX)

Date:  Sun, 2006-01-22

Dr. David E. Martin January 22, 2006 In their on-going effort to build knowledge economy focus both regionally and internationally, the DIFX invited M·CAM to present their IP-Backed Securities trading model for consideration by the exchange.

Dr. Martin addresses International IPR Policy Reforms at the Centre for Innovation, Incubation and Entrepreneurship Seminar Series

Date:  Mon, 2005-11-14

M·CAM and Darden Business School Case Studies Debut

Date:  Wed, 2005-11-02

M·CAM’s CEO and Fellow of the Batten Institute, David Martin and the University of Virginia’s Darden Graduate School of Business Administration’s Dean, Robert Bruner, have announced the publication of the first educational case studies emanating from the Batten Institute’s Intellectual Property in Business and Fincance fellowship program. Collaborating with faculty members Paul Simko and Mary Margaret Frank, these cases represent the critcal educational resources for business school curriculum. For more information on these cases, please refer to the following resources:

• For the Dupont Patent Donation Case Study, please refer to: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=908104
• For the GE Amersham Acquisition Case Study, please referto: https://store.darden.virginia.edu/business-case-study/general-electrics-acquisition-of-amersham-plc-3869

M·CAM tax shelter forensics contributes to unprecedented IRS settlement initiative

Date:  Fri, 2005-10-28

M·CAM Discusses Role of Innovation Risk Management

Date:  Thu, 2005-10-20

Dr. David E. Martin October 20, 2005 M·CAM Discusses Role of Innovation Risk Management in Federal Contracting and SBIR Phase III Programs with Partner, CIT. Innovative Partnerships 2005

M·CAM Comments on IRS Patent Donation Enforcement

Date:  Mon, 2005-10-17

Janet Novack Excerpted from Forbes – October 17, 2005 pg.56 For years the Internal Revenue Service tried to crack down on folks donating clunker cars to charity and taking inflated deductions. Now it’s doing the same to companies that took billions of dollars in charitable deductions for donating what could be clunker patents. The IRS has already disallowed $1 billion in patent deductions and is auditing another 50 companies that claimed $4.7 billion worth of contributions. The first public battle involves Procter & Gamble. In October 1999 P&G donated 40 patents involving injection moldings to the Milwaukee School of Engineering and claimed an $86.5 million charitable deduction. It predicted that revenues from their commercialization “could exceed $1 billion annually.” In fact, they were never commercialized. Advances in computerized machining have “pretty much passed” the technology by, says Vito Gervasi, who directs the Milwaukee school’s research in the area. Such appraisals, however, typically calculated the patents’ “market value” on the sales a hypothetical company with plants and distribution in place might reap–not their value to a not-for-profit, says David Martin, chief executive of patent valuation firm M·CAM, an IRS consultant. The valuations also ignored the fact that if there had been corporate buyers ready to pay so much for patents, they would have been sold, not donated. Martin says some companies took deductions for patents they retained an interest in (a clear no-no), for disputed patents and even for inventions they hadn’t won patents for. This kind of nonsense won’t be happening for long. Clunker Patents

M·CAM’s Martin and Pratt partner with IIMA’s Professor Anil Gupta to offer IP Executive Education Conference

Date:  Fri, 2005-09-30

Dr. Martin Addresses Global IP System Performance in India

Date:  Thu, 2005-09-29

Dr. David E. Martin September 29, 2005 Dr. David Martin addressed an audience of faculty, students, and national innovation leaders at a forum at the Indian Institute for Management – Ahmedabad. During his speech he called for the launch of India’s new “Salt March” on the 75th anniversary of Gandhi’s historical initiative to reclaim the economic and social rights of India. Drawing parallels between colonialism and the current WTO and TRIPS imbalances, Martin noted that India needs to find ways to redefine legacy patent systems so that all participants are protected rather than subjugated.

Launch of the Dubai International Financial Exchange (DIFX)

Date:  Mon, 2005-09-26

Dr. David E. Martin September 26, 2005 M·CAM Executive Management team, together with representatives of the M·CAM Board of Directors were invited to be present for the opening of the DIFX today. M·CAM is working with various entities in Dubai to support the Knowledge Economy initiatives and economic infrastructure priorities set forth by HH General Sheikh Mohammed Bin Rashid Al Maktoum, the Crown Prince of Dubai and UAE Defense Minister in his vision to build Dubai into a global knowledge economy hub. BusinessWeek online

M·CAM partners with The Bridge Ministry

Date:  Fri, 2005-09-23

M·CAM DOORS: A Tool for Patinformatics Described by SCIP

Date:  Thu, 2005-09-22

A ‘Robin Hood’ Declares War on Lucrative U.S. Patents

Date:  Fri, 2005-08-26

M·CAM CTO to chair session and present paper at International Symposium on Free/Open Source Software, Technologies and Content: FOSSTEC ’05

Date:  Sun, 2005-07-10

Patent Office Rejects Lipitor Patent on PUBPAT’s Request

Date:  Wed, 2005-06-22

PUBPAT Press Release June 22, 2005 In the reexamination proceeding initiated late last year by the Public Patent Foundation (“PUBPAT”), the United States Patent and Trademark Office has rejected all of the claims of Pfizer Inc.’s (NYSE: PFE) patent on Lipitor, touted by the pharmaceutical giant as being “the best-selling treatment for lowering cholesterol and the best-selling pharmaceutical product of any kind in the world.” Relying on evidence provided by PUBPAT when the reexamination was requested, the Patent Office rejected all 44 claims in the pharmaceutical giant’s patent. Pfizer has the opportunity to respond to the Patent Office’s rejection, but third party requests for reexamination, like the one filed by PUBPAT, result in having the subject patent either modified or completely revoked roughly 70% of the time. Although the rejected patent is one of five patents listed by Pfizer with the U.S. Food and Drug Administration (FDA) for atorvastatin, the generic name for the drug compound distributed under the Lipitor brand, it is the only one asserted by Pfizer in roughly two dozen patent infringement lawsuits filed last year against web sites selling generic atorvastatin to Americans. Two of the other listed patents are under review by a Delaware court and the remaining two have never been asserted by Pfizer against any competitor to Lipitor. “The Patent Office has agreed with our conclusion that it should have never granted Pfizer the Lipitor patent,” said Dan Ravicher, PUBPAT’s Executive Director. “Revoking Pfizer’s patent is a critical step towards providing American consumers with access to atorvastatin at a fair price, which will not only provide substantial economic benefit, but will also improve public health, as even Pfizer admits that many Americans in need of the drug are not getting it.” More information about the reexamination of Pfizer’s Lipitor patent, including a copy of the Patent Office’s Office Action rejecting all of its claims, can be found at http://www.pubpat.org/Protecting.htm. Contact: Jill Ratkevic, Bite Communications: (415) 365-0482; Jill.Ratkevic@bitepr.com. About PUBPAT: The Public Patent Foundation (“PUBPAT”) is a not-for-profit legal services organization working to protect the public from the harms caused by the patent system, particularly the harms caused by wrongly issued patents and unsound patent policy. PUBPAT provides the general public and those specific persons or businesses otherwise deprived of access to the system governing patents, with representation, advocacy, and education. To be kept informed of PUBPAT News, subscribe to the PUBPAT News List by sending an email with “subscribe” in the subject line to news-request@pubpat.org.

M·CAM CEO Lectures on Patent Keyword Obfuscation at Franklin Pierce Law Center

Date:  Thu, 2005-06-16

M·CAM CEO Comments on Dubai International Financial Exchange Pending Launch

Date:  Mon, 2005-06-06